Since constitutive activation of the PI3K/AKT/mTOR pathway is a major cause of vascular anomalies and overgrowth syndromes, the use of mTOR inhibitors, such as Sirolimus, appeared as a good therapeutic strategy (4). Here, PIK3CA is linked to overgrowth syndrome.